Prostate Cancer | Meet The Professor: Optimizing the Use of Hormonal Therapy in the Management of Prostate Cancer — Part 1
Featuring perspectives from Dr Matthew Smith, including the following topics: Introduction: Abemaciclib for Prostate Cancer? (0:00) Case: A man in his early 70s with a PSA of 150 ng/mL, Gleason 4 + 4 and upper abdominal adenopathy — Jennifer L Dallas, MD (9:30) Case: A man in his late 60s with Gleason 4 + 4, PSA of 147 ng/mL and a negative CT — David S Morris, MD (34:30) Case: A man in his late 60s with coronary artery disease and Gleason 4 + 4 who underwent external beam radiation therapy (EBRT) in 2013 and now has increasing PSA of 3.8 with a 6-month doubling time — Gurveen Kaur, MD (37:56) Case: A man in his mid 60s who experiences M0 progression after EBRT followed by androgen deprivation therapy (ADT) but refuses to continue ADT — Henna Malik, MD (41:44) Case: A man in his early 50s with a slowly rising PSA (now 1.31) after radical prostatectomy and salvage radiation therapy; PSMA PET scan denied by insurance, now appealed — Kapisthalam (KS) Kumar, MD (50:23) Case: A man in his late 70s with Gleason 5 + 4 and a PSA of 23 ng/mL increasing after EBRT followed by ADT, cryoablation and enzalutamide; after a response, 18F-fluciclovine PET shows subtle focus of uptake in left prostate — Susmitha Apuri, MD (57:06) CME information and select publications